Sarepta Therapeutics Launches 8th Annual Route 79 Scholarship Program for Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced the launch of the 8th annual Route 79 Scholarship Program for the 2025-2026 academic year. The program, named after the 79 exons of the dystrophin gene impacted by Duchenne muscular dystrophy (DMD), aims to support individuals living with DMD and their siblings as they pursue their educational goals.

The Route 79 Scholarship Program will award academic scholarships of up to $5,000 to as many as 20 individuals living with DMD and five siblings of individuals living with DMD. The scholarships will be awarded based on an applicant's community involvement, personal essay, and recommendation letter, with no consideration given to whether an applicant uses Sarepta products or therapies.

"Sarepta is committed to supporting the Duchenne community and helping individuals living with DMD and their families overcome the financial and emotional challenges that come with the disease," said Doug Ingram, president and chief executive officer of Sarepta Therapeutics. "The Route 79 Scholarship Program is just one way we're doing that, and we're proud to continue this tradition for the eighth year."

Applications for the 2025-2026 academic year will be accepted until May 15, 2025, at 11:59 p.m. PDT. Recipients will be notified prior to August 2025, and awards will be distributed directly to the school, college, or university in time for fall 2025 enrollment. Students may learn more about the program and how to apply by visiting sarepta.com/route79.

The Route 79 Scholarship Program is a key component of Sarepta Therapeutics' corporate social responsibility (CSR) initiatives, designed to support individuals living with DMD and their families as they pursue their educational goals. By providing financial assistance, the scholarship program helps to alleviate some of the financial burden that these individuals and their families may face due to the diagnosis and treatment of DMD. Additionally, the program aligns with Sarepta's mission to improve the lives of people with rare diseases and to support the Duchenne community.